Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038994 | 0.84 | ADORA1 (1.00) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| Potassium Ion SCHEMBL10806740 | 0.82 | ADORA2B (1.00) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL1321892 | 0.82 | ADORA2B (1.00) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL10806711 | 0.81 | ADORA2B (0.98) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL14129146 | 0.79 | ADORA2B (0.94) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL14564546 | 0.78 | ADORA2B (0.79) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL7318202 | 0.77 | ADORA2B (1.00) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL1948455 | 0.77 | ADORA2B (1.00) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL661108 | 0.77 | ADORA2B (1.00) | ADORA1ADORA2BADORA3ADORA2AKDM4E | |
| SCHEMBL7037638 | 0.76 | ADORA1 (0.78) | ADORA1ADORA2BADORA3ADORA2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-1308441-B1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | EISAI R&D MAN CO LTD (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7189717-B2 | Medicinal compositions promoting bowel movement | EISAI CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-7189717-B2 | Medicinal compositions promoting bowel movement | EISAI CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2007-03-08 | — | — | US | disclosed |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2007-03-08 | — | — | US | disclosed |
| US-7160892-B2 | Pyrimidone compounds and pharmaceutical compositions containing the same | EISAI CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7160892-B2 | Pyrimidone compounds and pharmaceutical compositions containing the same | EISAI CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2B 1/4885ADORA3 4/4885 |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | ADORA1 328/4885ADORA2B 307/4885ADORA3 129/4885 |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | ADORA1, ADORA2B, ADORA2A | ADORA1 1/4885ADORA2B 2/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.